




Docket No.: 271120US0PCT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313



ATTORNEYS AT LAW

J. DEREK MASON  
(703) 413-3000  
DMASON@OBLON.COM

RE: Application Serial No.: 10/532,104

Applicants: Naoki MATSUNAGA, et al.

Filing Date: April 21, 2005

For: N-{2-CHLORO-4-[(6,7-DIMETHOXY -4-  
QUINOLYL)OXY]PHENYL}-N'-(5-METHYL-3-  
ISOXAZOLYL)UREA SALT IN CRYSTALLINE  
FORM

Group Art Unit: 1614

Examiner: CHANG, Celia

SIR:

Attached hereto for filing are the following papers:

**Preliminary Amendment (9 pp.)**

Our check in the amount of -0- is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.

Norman F. Oblon

J. Derek Mason, Ph. D.

Registration No.: 35,270

Customer Number

**22850**

(703) 413-3000 (phone)  
(703) 413-2220 (fax)

**Daniel J. Pereira**  
**Registration No. 45,518**



DOCKET NO: 271120US0PCT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF :  
NAOKI MATSUNAGA, ET AL. : EXAMINER: CHANG, CELIA  
SERIAL NO: 10/532,104 :  
FILED: APRIL 21, 2005 : GROUP ART UNIT: 1625  
FOR: N-{2-CHLORO-4-[(6,7- :  
DIMETHOXY -4-  
QUINOLYL)OXY]PHENYL}-N' -(5-  
METHYL-3-ISOXAZOLYL)UREA SALT  
IN CRYSTALLINE FORM

PRELIMINARY AMENDMENT

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Prior to examination on the merits, and in conjunction with the discussion held with Examiner Chang on May 23, 2006, please amend the above-identified application as follows:

**Amendments to the Claims** are reflected in the listing of claims which begins on page 2 of this paper.

**Remarks/Arguments** begin on page 8 of this paper.